PATENT CLAIM ANALYSIS

Application Number: 15779369
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["536", "024500"]

Abstract:
The present invention relates to an N-Methyl-D-aspartate (NMDA) receptor antagonist, for use in the treatment of diseases associated with angiogenesis such as tumor angiogenesis, ocular neovascular disease, Age-related macular degeneration (AMD).

Claim (Index 4):
The method of  claim 10 , wherein the antagonist of NMDAR is selected from the group consisting of:\n i. a small organic molecule; ii. an anti-NMDAR antibody or antibody fragment; and iii. a polypeptide.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 93.0
- Lexical Diversity: 1.14706
- Patent Class: 536.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15747507', '14146223', '14146222', '15987932', '12876312']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6474633829322047
- 35 USC 102 Novelty (BERT): 0.4963392567426339
- Combined Prediction Score: 0.6323509703132477
- Mean Citation Score: 172.56750799999998
- Max Citation Score: 207.537
- Similarity Product: 127.69417609494928

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test